Smoking abstinence at longest · people who smoke
Varenicline leads to higher smoking abstinence at longest compared with placebo or no medication (high certainty).
1 finding from 1 review
Smoking abstinence at longest · people who smoke
Cytisine probably leads to higher smoking abstinence at longest compared with placebo or no medication (moderate certainty).
1 finding from 1 review
Incidence of retinopathy at 4 to 5 years · type 1 or type 2 diabetics
1 finding from 1 review
no estimate extracted
1 participants
GRADE not reported
Progression of retinopathy · type 1 or type 2 diabetics
1 finding from 1 review
no estimate extracted
1 participants
GRADE not reported
Combined incidence and progression of diabetic retinopathy by 5 years · type 1 or type 2 diabetics
1 finding from 1 review
no estimate extracted
1 participants
GRADE not reported
Incidence of PDR/CSME/VH by 5 years · type 1 or type 2 diabetics
1 finding from 1 review
no estimate extracted
1 participants
GRADE not reported
Change in visual loss associated with PSR: visual loss is defined by the deterioration of visual acuity of 3 lines or more with the Snellen chart · type 1 or type 2 diabetics
It is very uncertain whether blood pressure intervention/intensive blood pressure intervention changes visual acuity (loss of 3 lines or more) by 5 years compared with placebo/standard blood pressure intervention (very low certainty).
1 finding from 1 review
Adverse events—all‐cause mortality · type 1 or type 2 diabetics
1 finding from 1 review
no estimate extracted
1 participants
GRADE not reported
Adverse events: hypotension · type 1 or type 2 diabetics
Blood pressure intervention/intensive blood pressure intervention may leads to higher adverse events—hypotension compared with placebo/standard blood pressure intervention (low certainty).
1 finding from 1 review
QoL · adults aged 18 years and older receiving palliative care
1 finding from 1 review
Survival Log‐rank analysis Study enrolment to last date of · adults aged 18 years and older receiving palliative care
1 finding from 1 review
Adverse events NRS (scale from 0 to 10; lower score = less toxicity) · adults aged 18 years and older receiving palliative care
1 finding from 1 review
Mean daily rating of problem severity (lower score is better) · women with premenstrual syndrome (most met DSM‐V criteria for premenstrual dysphoric disorder (PMDD))
1 finding from 1 review
Mean change in daily rating of functional impairment: reduction of productivity (lower score is better) · women with premenstrual syndrome (most met DSM‐V criteria for premenstrual dysphoric disorder (PMDD))
1 finding from 1 review
Mean change in daily rating of functional impairment: social activities (lower score is better) · women with premenstrual syndrome (most met DSM‐V criteria for premenstrual dysphoric disorder (PMDD))
1 finding from 1 review
Mean change in daily rating of functional impairment: relationship interference (lower score is better) · women with premenstrual syndrome (most met DSM‐V criteria for premenstrual dysphoric disorder (PMDD))
1 finding from 1 review
Changes in Premenstrual Tension Scale scores (observer‐rated; lower score is better) · women with premenstrual syndrome (most met DSM‐V criteria for premenstrual dysphoric disorder (PMDD))
1 finding from 1 review
Changes in Premenstrual Tension Scale scores (self‐rated; lower score is better) · women with premenstrual syndrome (most met DSM‐V criteria for premenstrual dysphoric disorder (PMDD))
1 finding from 1 review
Withdrawals due to adverse events · women with premenstrual syndrome (most met DSM‐V criteria for premenstrual dysphoric disorder (PMDD))
Drospirenone plus ethinylestradiol may leads to higher withdrawal due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Death · patients on HD with HCV infection
Standard interferon showed no clear difference in death compared with placebo or control (low certainty).
1 finding from 1 review